13th July 2026

Nick, a 65-year-old man with type 2 diabetes and non-alcoholic fatty liver disease (steatosis), is on a sulphonylurea for glycaemic control.

Nick, a 65-year-old man with type 2 diabetes and non-alcoholic fatty liver disease (steatosis), is on a sulphonylurea for glycaemic control. He has recently experienced recurrent episodes of hypoglycaemia. How would you manage his sulphonylurea therapy to mitigate the risk of hypoglycaemia?

Select the SINGLE most appropriate option from the list below. Select ONE option only.